6:32 PM
 | 
Mar 24, 2015
 |  BC Extra  |  Clinical News

NGM to chart new course for lead compound

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) said its NGM282 met the primary endpoint in a Phase II trial to treat primary biliary cirrhosis (PBC), but now plans to study the compound to treat other Orphan bile acid-related diseases. The company said PBC patients may have treatment alternatives before NGM282...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >